当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

Abstract：

PURPOSE:Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma. METHODS:Cisplatin concentrations were determined in plasma and ultrafiltrate samples collected on each of six cycles of a monotherapy regimen, beginning with a dose of 1.6 mg/kg at 16 days of age. Pharmacokinetic data were analyzed to generate clearance (CL) and area under the curve (AUC0-∞) for each administration. Toxicity and clinical response were monitored. RESULTS:The first cisplatin dose (1.6 mg/kg) resulted in an AUC0-∞ of 535 µg/mL · min, was well tolerated and associated with a good response. This AUC was, therefore, considered as an appropriate target for this patient. Increases in cisplatin CL were observed across consecutive treatment cycles, and, therefore, dose was gradually increased to finally reach 2.5 mg/kg on the sixth cycle. Treatment was well tolerated over the six courses and resulted in a good response, with the patient remaining in remission at 15 months. Cisplatin CL was significantly correlated to age (p = 0.013) and weight (p = 0.013). CONCLUSIONS:Our study provides useful data on the pharmacokinetics of cisplatin monotherapy in neonates treated within the first few weeks of life. These data provide a reference point to support clinicians in determining appropriate dosing regimens for neonates and support the implementation of therapeutic drug monitoring in such challenging patients.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Thomas F,Veal GJ,El Balkhi S,Lafont T,Picard N,Brugières L,Chatelut E,Piguet C

doi

10.1007/s00280-018-3625-5

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

361-365

issue

2

eissn

0344-5704

issn

1432-0843

pii

10.1007/s00280-018-3625-5

journal_volume

82

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.

    abstract：INTRODUCTION:Monoclonal antibodies (MAbs) targeting epidermal growth factor receptor (EGFR) are effective in treatment of metastatic colorectal cancer (mCRC). Cetuximab, a chimeric MAb targets EGFR. Even with premedication, cetuximab can cause a hypersensitivity reaction (HSR). In case of severe HSR, further therapy wi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0831-6

    authors： Saif MW,Peccerillo J,Potter V

    更新日期：2009-05-01 00:00:00

  • Adriamycin-lipiodol suspension for i.a. chemotherapy of hepatocellular carcinoma.

    abstract：:Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifyi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00451648

    authors： Katagiri Y,Mabuchi K,Itakura T,Naora K,Iwamoto K,Nozu Y,Hirai S,Ikeda N,Kawai T

    更新日期：1989-01-01 00:00:00

  • Dibromodulcitol plus bleomycin compared with bleomycin alone in head and neck cancer.

    abstract：:Advanced recurrent squamous cell head and neck cancer patients were prospectively randomized to receive or not receive dibromodulcitol 10 mg/kg PO weekly for 8 consecutive weeks in addition to bleomycin chemotherapy. Patients initially entered in the study received bleomycin 15 mu/m2 three times weekly for 8 weeks. Th...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00255478

    authors： Issell BF,Borsos G,D'Aoust JC,Banhidy F,Crooke ST,Eckhardt S

    更新日期：1982-01-01 00:00:00

  • A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.

    abstract：PURPOSE:Inhibitors of DNA (cytosine-5)-methyltransferases (DNMT) are active antineoplastic agents. We conducted the first-in-human phase I trial of 5-fluoro-2'-deoxycytidine (FdCyd), a DNMT inhibitor stable in aqueous solution, in patients with advanced solid tumors. Objectives were to establish the safety, maximum tol...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-014-2674-7

    authors： Newman EM,Morgan RJ,Kummar S,Beumer JH,Blanchard MS,Ruel C,El-Khoueiry AB,Carroll MI,Hou JM,Li C,Lenz HJ,Eiseman JL,Doroshow JH

    更新日期：2015-03-01 00:00:00

  • Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.

    abstract：PURPOSE:To compare the response, survival, hematological and non-hematological toxicities of gemcitabine administrated at fixed-dose rate infusion (10 mg/m(2)/min, FDR) and standard 30 min infusion in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Electronic databases of MEDLINE, EMBASE and Cochran...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,meta分析

    doi：10.1007/s00280-012-1974-z

    authors： Qiu MT,Ding XX,Hu JW,Tian HY,Yin R,Xu L

    更新日期：2012-12-01 00:00:00

  • Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.

    abstract：PURPOSE:To evaluate the efficacy and safety of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin. METHODS:The FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m(2) on day 1 plus leucovorin (LV) 400 mg/m(2) on day 1 plus 5-fluorouracil (5-FU...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1301-5

    authors： Bao HY,Fang WJ,Zhang XC,Shi GM,Huang S,Yu LF,Chen J,Mou HB,Deng J,Shen P,Xu N

    更新日期：2011-01-01 00:00:00

  • Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.

    abstract：PURPOSE:To assess the effect of elotuzumab on corrected QT (QTc) intervals and cardiac safety. METHODS:Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (tre...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3182-8

    authors： Passey C,Darbenzio R,Jou YM,Lynch M,Gupta M

    更新日期：2016-12-01 00:00:00

  • Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.

    abstract：:The risk of potential drug-drug interactions (PDI) is poorly studied in oncology. We included 105 patients with advanced non-small-cell lung cancer (NSCLC), 100 patients with advanced breast cancer (BC) and 100 patients of the palliative care unit (PCU) receiving systemic palliative treatment between 2010 and 2015. Al...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03783-9

    authors： Hoemme A,Barth H,Haschke M,Krähenbühl S,Strasser F,Lehner C,von Kameke A,Wälti T,Thürlimann B,Früh M,Driessen C,Joerger M

    更新日期：2019-04-01 00:00:00

  • FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.

    abstract：OBJECTIVE:To investigate the effects of FSTL1-mediated NF-κB signaling pathway on cisplatin (DDP) sensitivity of EOC cells. METHODS:FSTL1 expression was determined in epithelial ovarian cancer (EOC) tissues and corresponding adjacent tissues using immunohistochemistry. SKOV3 and SKOV3/DDP cells were transfected and gr...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-020-04215-9

    authors： Liu YK,Jia YJ,Liu SH,Ma J

    更新日期：2021-01-03 00:00:00

  • LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.

    abstract：PURPOSE:The chimeric protein BCR-ABL, a constitutively active protein-tyrosine kinase, triggers downstream signalling proteins, such as STAT3, ultimately resulting in the survival of myeloid progenitors in BCR-ABL-positive leukemias. Here, we evaluated the effect of LLL-3, an inhibitor of STAT3 activity, on cell viabil...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-1109-3

    authors： Mencalha AL,Du Rocher B,Salles D,Binato R,Abdelhay E

    更新日期：2010-05-01 00:00:00

  • Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

    abstract：:S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-003-0617-9

    authors： Peters GJ,Noordhuis P,Van Kuilenburg AB,Schornagel JH,Gall H,Turner SL,Swart MS,Voorn D,Van Gennip AH,Wanders J,Holwerda U,Smid K,Giaccone G,Fumoleau P,Van Groeningen CJ

    更新日期：2003-07-01 00:00:00

  • V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.

    abstract：:Bizelesin (U-77779) is a highly potent bis-alkylating antitumor agent that is effective against several tumor systems in vitro and in vivo. V79 cells that were 125- to 250-fold resistant to bizelesin developed after constant exposure to gradually increasing concentrations of the drug. Resistant cells exhibited a multi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686110

    authors： Butryn RK,Smith KS,Adams EG,Abraham I,Stackpole J,Sampson KE,Bhuyan BK

    更新日期：1994-01-01 00:00:00

  • A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.

    abstract：PURPOSE:The antifolate pralatrexate (10-propargyl-10-deazaaminopterin, PDX) demonstrates greater in vitro and in vivo antitumor efficacy than methotrexate. Preclinical models indicated that the efficacy of pralatrexate may be enhanced by coadministration with probenecid. The aim of this phase I study was to determine t...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0080-x

    authors： Fury MG,Krug LM,Azzoli CG,Sharma S,Kemeny N,Wu N,Kris MG,Rizvi NA

    更新日期：2006-05-01 00:00:00

  • Salivary passage of 5-fluorouracil during continuous infusion.

    abstract：:Plasmatic and salivary concentrations of 5-FU were investigated in ten patients given 5-day continuous infusions of 5-fluorouracil (5-FU) (1 g/m2/day). Measurable concentrations of salivary 5-FU were scattered ranging from 6 to 100 ng/ml. Between individual 5-FU concentrations in saliva and plasma the coefficient of c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00300243

    authors： Milano G,Thyss A,Santini J,Frenay M,Francois E,Schneider M,Demard F

    更新日期：1989-01-01 00:00:00

  • Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.

    abstract：PURPOSE:The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced m...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-003-0678-9

    authors： Spieth K,Kaufmann R,Gille J

    更新日期：2003-11-01 00:00:00

  • The effect of cytostatic drug treatment on intestine-specific transcription factors Cdx2, GATA-4 and HNF-1alpha in mice.

    abstract：:Chemotherapy-induced intestinal damage is a very important dose-limiting side effect for which there is no definitive prophylaxis or treatment. This is in part due to the lack of understanding of its pathophysiology and impact on intestinal differentiation. The objective of this study was to investigate the gene expre...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0119-z

    authors： de Koning BA,Lindenbergh-Kortleve DJ,Pieters R,Rings EH,Büller HA,Renes IB,Einerhand AW

    更新日期：2006-06-01 00:00:00

  • Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL).

    abstract：PURPOSE:To investigate the antitumor effects of tyroserleutide (tyrosyl-seryl-leucine, YSL) on human Bel7402 hepatocarcinoma in vitro and in vivo, with preliminary exploration of its antitumor mechanism. METHODS:MTT was used to observe the anticarcinogenic effects of YSL on human hepatocarcinoma Bel7402 cells in vitro...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0046-z

    authors： Lu R,Jia J,Bao L,Fu Z,Li G,Wang S,Wang Z,Jin M,Gao W,Yao Z

    更新日期：2006-01-01 00:00:00

  • Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.

    abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3471-x

    authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

    更新日期：2017-12-01 00:00:00

  • Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity.

    abstract：:BS compounds, a series of new dihydropyridines, successfully overcame multidrug resistance in P388/ADR cells in vitro. These agents synergistically potentiated the cytotoxicity of Adriamycin to P388/ADR cells at a concentration of 1-2 microM, whereas they showed hardly any synergistic effect in the parental cell line ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257444

    authors： Yoshinari T,Iwasawa Y,Miura K,Takahashi IS,Fukuroda T,Suzuki K,Okura A

    更新日期：1989-01-01 00:00:00

  • Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.

    abstract：PURPOSE:Sarcomas are a rare and heterogeneous variant of cancer. The standard of care treatment involves surgical resection with radiation in high-risk patients. Despite appropriate treatment approximately 50 % of patients will suffer and die from recurrent disease. The purpose of this article is to review the current ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s00280-016-3055-1

    authors： Nathenson MJ,Sausville E

    更新日期：2016-11-01 00:00:00

  • Clinical pharmacology of intracarotid etoposide.

    abstract：:Pharmacokinetics studies were performed in ten patients who received VP-16 by intracarotid infusion at 100-300 mg/m2. VP-16 was analyzed by high-pressure liquid chromatography. ESTRIP and NONLIN were used to characterize VP-16 pharmacokinetics. VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the tot...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00293995

    authors： Savaraj N,Feun LG,Lu K,Wallace S,Fields WS,Loo TL

    更新日期：1986-01-01 00:00:00

  • Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy.

    abstract：BACKGROUND:TAP chemotherapy (paclitaxel, doxorubicin, and cisplatin) is effective for advanced and recurrent endometrial carcinoma, but has occasional severe toxicity. TEC chemotherapy (paclitaxel, epirubicin, and carboplatin) has been suggested to have less toxicity; however, the optimal dosage has yet to be determine...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-011-1638-4

    authors： Egawa-Takata T,Ueda Y,Kuragaki C,Miyake T,Miyatake T,Fujita M,Yoshino K,Nakashima R,Okazawa M,Tsutsui T,Morishige K,Kimura T,Yamasaki M,Nishizaki T,Nagamatsu M,Ito K,Asada M,Ogita K,Wakimoto A,Yamamoto T,Nishio Y

    更新日期：2011-12-01 00:00:00

  • Morphonuclear characterization of drug resistance by means of digital cell-image analysis: an in vitro assessment.

    abstract：:The prediction of tumor resistance to antineoplastic drugs remains an important challenge in cancer chemotherapy. Several methods have been proposed in this connection, but they present a number of problems such as clinical relevance and applicability. In the present work we put forward an original methodology to asse...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685647

    authors： Pauwels O,Kiss R

    更新日期：1995-01-01 00:00:00

  • Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.

    abstract：PURPOSE:Methotrexate polyglutamates (MTXpg) facilitate incorporation of thioguanine nucleotides into DNA (DNA-TG, the primary cytotoxic thiopurine metabolite and outcome determinant in MTX/6-mercaptopurine treatment of childhood ALL). We hypothesized that mapping erythrocyte levels of MTXpg with 1-6 glutamates and thei...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3704-7

    authors： Nersting J,Nielsen SN,Grell K,Paerregaard M,Abrahamsson J,Lund B,Jonsson OG,Pruunsild K,Vaitkeviciene G,Kanerva J,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

    更新日期：2019-01-01 00:00:00

  • Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.

    abstract：PURPOSE:To evaluate the population pharmacokinetics of pemetrexed disodium in cancer patients enrolled in four different open-label, multicenter, nonrandomized phase II studies. METHODS:Pemetrexed disodium was administered as a 10-min intravenous infusion (600 mg/m2) every 21 days. A total of four blood samples were t...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800000144

    authors： Ouellet D,Periclou AP,Johnson RD,Woodworth JR,Lalonde RL

    更新日期：2000-01-01 00:00:00

  • A phase II study of temozolomide in hormone-refractory prostate cancer.

    abstract：INTRODUCTION:Hormone-refractory disseminated prostate cancer is a major oncological problem. Preclinical studies with temozolomide, an oral alkylating agent, in prostate cancer have shown encouraging results. In phase I studies the safety of temozolomide in non-prostate cancer patients has been demonstrated. Based on t...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800051027

    authors： van Brussel JP,Busstra MB,Lang MS,Catsburg T,Schröder FH,Mickisch GH

    更新日期：2000-01-01 00:00:00

  • Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo.

    abstract：:PSC-833, a non immunosuppressive analogue of cyclosporin A, is an effective modulator of the multidrug-resistant tumor phenotype. Since both PSC-833 and cyclosporin A also enhance the cytotoxicity of VP-16 against drug sensitive L1210 leukemia cells in vitro we compared these agents as modulators of VP-16 efficacy in ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050597

    authors： Slater LM,Sweet P,Stupecky M,Osann K

    更新日期：1997-01-01 00:00:00

  • Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors.

    abstract：:Intravenous (i.v.) administration of sodium thiosulfate reduces the toxicity of cis-diamminedichloroplatinum (II) (CDDP). This effect, which allows the use of increased CDDP doses, has been exploited clinically in the intraperitoneal (i.p.) treatment of intraabdominal tumors. Recently, attempts have been made to treat...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257358

    authors： Aamdal S,Fodstad O,Pihl A

    更新日期：1988-01-01 00:00:00

  • In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

    abstract：PURPOSE:In clinical trials, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administered concomitantly with first-line cytotoxicity chemotherapy failed to confer a survival benefit to patients with non-small-cell lung cancer (NSCLC). The aim of this study was to test whether paclitaxel followe...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1347-4

    authors： Cheng H,An SJ,Zhang XC,Dong S,Zhang YF,Chen ZH,Chen HJ,Guo AL,Lin QX,Wu YL

    更新日期：2011-03-01 00:00:00

  • Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo.

    abstract：PURPOSE:To investigate the effect of the antihistamine ketotifen on multidrug resistance in human breast cancer cells and doxorubicin toxicity in mice. METHODS:Clonogenicity assays were used to test the effect of ketotifen on human multidrug resistant breast cancer cell lines exposed to chemotherapeutic agents. Flow c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0600-5

    authors： Zhang Y,Berger SA

    更新日期：2003-05-01 00:00:00